Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.

A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.

Hair loss treatment using 1.25 Finasteride Teva daily, Folcare Minoxidil 5% 2x a day, dermarolling, Nizoral, Hask biotin boost shampoo, and 5000mg biotin pill. User unsure if experiencing regrowth or just growth, especially in crown area.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A user shared their positive experience with a crown MicroFUE hair transplant at Boston Hair Restoration, highlighting the smooth procedure, minimal pain, and significant growth over 12 months. They used oral minoxidil, finasteride (transitioning to dutasteride), PRP sessions, and a LaserCap, achieving excellent results and full confidence.

A user did not respond to finasteride, dutasteride, and oral minoxidil for hair loss after four years of treatment and is considering scalp micropigmentation (SMP). Other users suggest the hair loss pattern may indicate alopecia areata and recommend seeing a dermatologist.

A 19-year-old trans man has been using Finasteride 1mg for a little over two months and is concerned about worsening hair loss, noting a fuzzy and soft hairline and crown. The user is upset as the hair loss appears worse than before starting the treatment.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

A 34-year-old man has been using oral minoxidil and finasteride for three months with noticeable hair regrowth and no side effects. He is considering a hair transplant but is currently satisfied with the progress and prefers not to switch to more aggressive treatments.

The conversation is about considering pyrilutamide 1% as an alternative treatment for hair loss due to intolerance to 5-alpha reductase inhibitors. Some users suggest it might be effective, while others view it as a temporary solution.

The user is considering a second hair transplant or scalp micropigmentation to address thinning in the crown area and hide scars from a previous transplant. They have been using finasteride and minoxidil for three years but are concerned about the appearance of their donor area and the effectiveness of scalp micropigmentation.

The conversation discusses starting low-dose oral finasteride for hair loss, considering hormone levels and potential side effects like gynecomastia. Suggestions include using DIM for estradiol, vitamin B6 for prolactin, and lifestyle changes to optimize hormone profiles before starting treatment.

A user with diffuse thinning, currently using finasteride, biotin, minoxidil, and nizoral shampoo, is considering a topical solution called "82M" but is skeptical due to its high cost and lack of supporting research. They seek others' experiences with "82M."

Hair loss treatments, specifically the use of finasteride, microneedling and potentially oral minoxidil. People discussed their experiences with finasteride, its effects on sexual behaviors, as well as potential solutions such as tadalafil or using other growth factor signal peptides for hope in curing male pattern baldness.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

The user has been taking 2.5 mg of dutasteride for 6 months and using minoxidil topically for 3 years but hasn't seen significant hair regrowth, only a slight decrease in hair loss. Suggestions include switching to oral minoxidil, adding microneedling, or using growth agonists like bimatoprost to improve results.

The user is using a combination of 7% minoxidil, 0.2% finasteride, 0.5mg finasteride, RU58841, and daily microneedling but is not seeing hair regrowth after 5 months. Suggestions include being patient, reducing microneedling frequency, considering oral minoxidil, and possibly switching to dutasteride if no improvement after a year.

A 19-year-old male shared his 10-month progress using finasteride, starting at 0.25mg and increasing to 1.25mg daily, noting new hair growth at the temples. He experienced a significant shed at 6 months but reported no side effects from increasing the dosage.

The user tried minoxidil 5% for 3 years with little improvement, then switched to a 15% minoxidil with 0.1% finasteride solution once daily and started using pyrilutamide, resulting in significant hair regrowth over time. They are considering a hair transplant but are continuing with topical treatments to maximize hair growth first.

A 20-year-old male has been using 1mg finasteride and 5% minoxidil daily for 1.5 to 8 months and is unsure about regrowth. Suggestions include continuing the treatment, trying microneedling, or considering oral minoxidil.

A user underwent a hair transplant at Moart Clinic in Seoul, receiving 1100 grafts in the crown area after Dutasteride and oral Minoxidil failed to improve a stubborn bald spot. The procedure was successful, with minimal pain and good post-op recovery, costing $6900 USD before a tax refund.

A 21-year-old male shares progress pictures showing improvement in hair growth using daily topical minoxidil 5%, microneedling 1.25mm, and 500mg of saw palmetto. He reports new and healthy hair growth, indicating success in managing androgenic alopecia.

A user's successful hair loss treatment using ketoconazole shampoo, 0.5mg finasteride, and 5% liquid minoxidil. They noticed significant results after 4 months, with reduced hair fall observed earlier.

A user shared their impressive hair regrowth progress after 5 months using 1mg oral finasteride every other day, 2.5mg oral minoxidil daily, weekly dermastamping, and daily scalp massages. They reported no side effects and began seeing improvement after 2.5 months.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.

A 22-year-old male has been experiencing hair thinning since 18 and was prescribed 50mg oral spironolactone for hair loss and high blood pressure, despite inquiring about finasteride. A reply suggests that spironolactone is less effective than finasteride and minoxidil for hair loss and recommends seeking a second medical opinion.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

The user is experiencing hair shedding despite starting finasteride 4 months ago, with no signs of miniaturization. They are seeking advice after normal blood tests and similar family experiences.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.